Clinical Trial Update: Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating Epimedium prenylflavonoid (EP) extract for osteoporosis and cardiovascular disease; the sponsor is National University Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Osteoporosis

Drugs mentioned

• Epimedium Prenylflavonoid (EP) Extract (Epimedium prenylflavonoid extract)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Osteoporosis, Cardiovascular Disease | Phase 1 | Status: UNKNOWN